Biotest AG: Preliminary Results
Biotest AG / Preliminary Results
14.07.2010 09:36
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Dreieich, Germany, 14 July 2010. According to preliminary figures, the
Biotest Group recorded a slight revenue increase of 4% in the first half of
2010, taking sales to EUR227.1 million (first half of 2009: EUR218.4
million). The Group generated earnings before interest and taxes (EBIT) of
EUR23.7 million (previous year: EUR31.2 million. Earnings fell short of
the Company's expectations, reflecting the further downturn in prices for
plasma proteins.
Market developments are expected to remain modest in the second half of the
year. Due to both this and the moderate additional impact of the German act
to modify statutory health insurance as part of the German healthcare
reform (GKV-Änderungsgesetz*), the Board of Management has adjusted its
earnings target for the continuing operations for the full year 2010.
The Biotest Group still anticipates low, single-digit sales growth compared
with the previous year (sales 2009: EUR438.6 million) and EBIT totalling
EUR45 million (+/-10%) (2009: EUR61.6 million). Biotest had previously
anticipated for the full year 2010 to generate EBIT on a par with the
previous year. All figures relate to continuing operations.
In discontinued operation, EBIT will be up to now at EUR18.4 million for
financial year 2010 due to profits from the disposal of the Company's
transfusion and transplantation diagnostics activities. EBIT from
discontinued operation has to be added to the anticipated EBIT from
continuing operations.
* GKV-Änderungsgesetz - German act to modify statutory health insurance and
other regulations (Statutory Health Insurance Restructuring Act)
Biotest Aktiengesellschaft
The Board of Management
Biotest AG
Landsteinerstr. 5
63303 Dreieich, Germany
www.biotest.de
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/ regulated market
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
14.07.2010 Ad hoc announcement, Financial News and Press Release distributed by DGAP.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
